Intercell

Intercell AG was an Austrian biotechnology company headquartered in Vienna and focused on the research, development, and commercialization of vaccines and related biological technologies. The company was established in 1998 as a spin-off from the Research Institute of Molecular Pathology in Vienna. Its activities covered prophylactic vaccines, therapeutic vaccine candidates, antigen-discovery programs, and adjuvant or vaccine-delivery technologies. Intercell operated in a field requiring long development timelines, substantial clinical investment, and partnerships with larger pharmaceutical companies. Its stated focus was on infectious diseases for which improved prevention or treatment could address significant public-health and travel-related needs. Research programs referenced in company and encyclopedia materials included vaccines and vaccine candidates for Japanese encephalitis, hepatitis C, hepatitis B, pneumonia, pandemic influenza, and other infectious diseases. The company also developed technology intended to improve the delivery or effectiveness of vaccines, including a vaccine-enhancement patch program. One of Intercell's most visible achievements was the development of a Japanese encephalitis vaccine commonly identified as IC51. The product received approvals in Europe, the United States, and Australia and was commercialized in different markets under names including IXIARO and JESPECT. Intercell also pursued a therapeutic hepatitis C vaccine that had reached Phase II clinical development, as well as antigen-identification and adjuvant technologies intended to support its broader vaccine pipeline. The company collaborated with major pharmaceutical and public-sector organizations. Materials associated with Intercell describe cooperation with Novartis, Merck, and Sanofi-Aventis on vaccine production or development. Its pandemic-influenza vaccine-enhancement patch program was conducted in collaboration with the United States Department of Health and Human Services and had reached Phase II clinical development according to the cited reference material. Intercell became a publicly traded company on the Vienna Stock Exchange on February 28, 2005. During the following years it continued to combine internal research with licensing, commercial partnerships, and potential acquisitions. In 2008, it signaled an intention to acquire Iomai, a Maryland-based developer of needle-free vaccination technology. The transaction formed part of Intercell's effort to broaden its delivery-technology capabilities, although the supplied reference material does not establish that the acquisition was completed. Intercell ultimately ceased to exist as an independent corporate brand. In 2012, it merged with the French biotechnology company Vivalis SE to create Valneva SE. The merger combined the companies' vaccine and biotechnology activities, and Intercell's independent corporate identity was subsequently absorbed into the Valneva organization. Intercell is therefore best understood as a defunct vaccine-focused biotechnology company whose principal legacy lies in its Japanese encephalitis vaccine, infectious-disease pipeline, and vaccine-platform technologies.

Intercell was created in Vienna in 1998 as a spin-off of the Research Institute of Molecular Pathology. From its beginning, the company was organized around vaccine research and the development of biological products for infectious diseases. Its model combined in-house scientific work with external development, manufacturing, and commercialization relationships, a structure common among biotechnology companies whose products require extensive laboratory research, clinical trials, regulatory review, and specialized production capacity. The company's portfolio included both conventional prophylactic vaccine programs and more exploratory biotechnology projects. Intercell worked on products and candidates associated with Japanese encephalitis, hepatitis B, hepatitis C, pneumonia, and pandemic influenza. Its research agenda also included antigen-identification methods and adjuvant technologies. These platform activities were intended to improve the discovery of vaccine targets and strengthen immune responses, rather than being limited to a single marketed product. Intercell's leading commercial achievement was its IC51 Japanese encephalitis vaccine. The vaccine was approved in Europe, the United States, and Australia and was sold under market-specific names including IXIARO and JESPECT. Japanese encephalitis vaccination was particularly relevant to travelers and populations exposed to the disease, giving the product an international market role. In addition to this vaccine, Intercell pursued a therapeutic vaccine for hepatitis C, which had entered Phase II clinical development according to the supplied reference material. Intercell also developed delivery and enhancement technologies. Its Vaccine Enhancement Patch program sought to improve the prevention of pandemic influenza and was developed with the United States Department of Health and Human Services. The program had reached Phase II clinical development in the cited material. The company further cooperated with pharmaceutical businesses including Novartis, Merck, and Sanofi-Aventis in connection with vaccine production or development. Such relationships enabled a relatively specialized biotechnology company to access broader manufacturing, regulatory, and commercial capabilities. The company entered the public markets on the Vienna Stock Exchange on February 28, 2005. Public listing gave Intercell access to capital for clinical development and supported its profile as one of Austria's biotechnology companies. Its later strategy included evaluating external technologies and possible acquisitions. In 2008, Intercell signaled that it intended to acquire Iomai, a Maryland-based company working on needle-free vaccination technology. The available reference does not establish whether that proposed acquisition was completed, so it is best treated as a strategic initiative rather than a confirmed completed transaction. Intercell's independent history ended through a corporate combination rather than a simple shutdown. In 2012, it merged with Vivalis SE, a French biotechnology company, to form Valneva SE. The combination brought together the two companies' vaccine and biological-product activities. After the merger, Intercell was no longer an independent listed biotechnology company or continuing standalone brand. Its Japanese encephalitis vaccine and other technology assets became part of the successor company's broader vaccine business. Intercell's legacy is consequently associated with Austrian vaccine innovation, the development of IC51, infectious-disease research, and the use of partnerships and platform technologies to advance biomedical products.

• 2012

  Merger with Vivalis creates Valneva

  [1]Intercellen.wikipedia.org

  Intercell merged with Vivalis SE, bringing the independent Intercell company and brand into the newly formed Valneva SE.

• 2008

  Iomai acquisition initiative

  [1]Intercellen.wikipedia.org

  Intercell signaled an intention to acquire Iomai, a Maryland company developing needle-free vaccination technology; completion is not established by the supplied source.

• 2005

  Public listing on the Vienna Stock Exchange

  [1]Intercellen.wikipedia.org

  Intercell AG became listed on the Vienna Stock Exchange on February 28, 2005.

• 1998

  Intercell is established as a research spin-off

  [1]Intercellen.wikipedia.org

  Intercell was formed in Vienna as a spin-off from the Research Institute of Molecular Pathology and began work on vaccines and related biological products.

A research-led biotechnology company specializing in vaccines, infectious-disease prevention, therapeutic vaccine programs, and enabling technologies such as adjuvants and vaccine-delivery systems.

• Japanese encephalitis vaccine

  IC51

  IC51 was Intercell's principal Japanese encephalitis vaccine. It was approved in Europe, the United States, and Australia and was commercialized under names including IXIARO and JESPECT. The product represented the company's most prominent transition from vaccine research into an internationally marketed infectious-disease prevention product.

• Japanese encephalitis vaccine

  IXIARO

  IXIARO was one of the commercial names used for Intercell's IC51 Japanese encephalitis vaccine. It was positioned for prevention of Japanese encephalitis, including use by travelers and others at risk of exposure, and received regulatory approval in several major markets.

• Japanese encephalitis vaccine

  JESPECT

  JESPECT was a market-specific commercial name associated with Intercell's IC51 Japanese encephalitis vaccine. It formed part of the company's international vaccine commercialization effort and was approved in Australia according to the supplied reference material.

• Therapeutic vaccine candidate

  Hepatitis C therapeutic vaccine

  Intercell developed a therapeutic vaccine candidate for hepatitis C. The program had reached Phase II clinical development in the cited reference material, but the supplied sources do not provide a later development outcome or commercial launch.

• Vaccine-delivery and immune-enhancement technology

  Vaccine Enhancement Patch

  The Vaccine Enhancement Patch was an Intercell program intended to improve prevention of pandemic influenza. It was developed in collaboration with the United States Department of Health and Human Services and had reached Phase II clinical development according to the supplied reference.

• Vaccine platform technology

  Antigen identification and adjuvant technologies

  Intercell maintained platform activities focused on identifying vaccine antigens and developing adjuvant technologies. These capabilities supported the company's broader infectious-disease pipeline and were intended to improve the design and immune performance of vaccine products.

• 2012

  Merger with VivalisM&A

  Background

  Intercell and Vivalis were biotechnology companies with complementary vaccine and biological-product activities.

  Action taken

  Intercell merged with Vivalis SE to create Valneva SE.

  Aftermath

  The merger ended Intercell's existence as an independent company and transferred its activities and assets into Valneva.

  Source

• 2008

  Proposed expansion into needle-free vaccination technologyM&A

  Background

  Intercell was developing vaccine products while also seeking technologies that could broaden its delivery capabilities. Iomai, based in Maryland, was associated with needle-free vaccination technology.

  Action taken

  Intercell signaled its intention to acquire Iomai. The available reference does not confirm that the proposed acquisition was completed.

  Aftermath

  The supplied material does not document the final outcome of the proposal, so no completed-transaction or financial conclusion is recorded.

  Source

• 2021.03.26

  Reported2021.03.26

  Intercell collaborates with ISBM institutions on virtual mentoring[2]Intercell与ISBM机构合作提供虚拟导师服务aninews.in

  Intercell and ISBM University and Indian School of Business Management and Administration announced a collaboration to offer virtual mentoring sessions to their registered postgraduate students.

Read more

1. 1Intercellen.wikipedia.org
2. 2Intercell与ISBM机构合作提供虚拟导师服务aninews.in